Post-bariatric hypoglycaemia (PBH) is associated with challenging management and largely empirical treatment options, though evidence on effective therapies remains limited. To address explore this, a study evaluated the efficacy and safety of acarbose and canagliflozin in 11 participants with PBH. The study found that neither canagliflozin nor acarbose significantly reduced time spent in hypoglycaemia compared to placebo, with median time below 3.9 mmol/L at 2.6% during screening, 1.2% with placebo, 1.1% with acarbose, and 0.8% with canagliflozin.
However, both treatments showed improvements in secondary outcomes, including increased time in range, reduced glycaemic variability, and fewer hypoglycaemia symptoms, particularly with canagliflozin. Acarbose was associated with moderate side effects leading to discontinuation in one participant, while no severe adverse events were reported…
